Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-05
DOI
10.3389/fonc.2019.00475
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the IGF1R/PI3K/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors
- (2019) Sudan N Loganathan et al. MOLECULAR CANCER THERAPEUTICS
- Patient-derived organoid models help define personalized management of gastrointestinal cancer
- (2018) M. R. Aberle et al. BRITISH JOURNAL OF SURGERY
- Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
- (2018) Gwen Lomberk et al. Nature Communications
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
- (2017) Rémy Nicolle et al. Cell Reports
- Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers
- (2016) Eugene J. Koay et al. CANCER LETTERS
- CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
- (2016) Elisa M Noll et al. NATURE MEDICINE
- Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma
- (2015) Pauline Duconseil et al. AMERICAN JOURNAL OF PATHOLOGY
- Genetics and Biology of Pancreatic Ductal Adenocarcinoma
- (2015) Richard F. Dunne et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
- (2015) P L Garcia et al. ONCOGENE
- Stratification of pancreatic tissue samples for molecular studies: RNA-based cellular annotation procedure
- (2015) Anette Heller et al. PANCREATOLOGY
- Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
- (2015) Irawati Kandela et al. eLife
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer
- (2014) Barbara Bournet WORLD JOURNAL OF GASTROENTEROLOGY
- Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure
- (2014) J. Qi Cold Spring Harbor Perspectives in Biology
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Evolution and dynamics of pancreatic cancer progression
- (2013) S Yachida et al. ONCOGENE
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started